Drug Profile
Research programme: bispecific antibodies - Genmab/Novartis
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Genmab; Novartis
- Developer Genmab
- Class Bispecific antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Denmark
- 04 Jun 2012 Early research in Undefined indication in Denmark (unspecified route)